In-Silico Identification of Novel Pharmacological Synergisms: The Trabectedin Case.

ABSTRACT: The in-silico strategy of identifying novel uses for already existing drugs, known as drug repositioning, has enhanced drug discovery. Previous studies have shown a positive correlation between expression changes induced by the anticancer agent trabectedin and those caused by irinotecan, a topoisomerase I inhibitor. Leveraging the availability of transcriptional datasets, we developed a general in-silico drug-repositioning approach that we applied to investigate novel trabectedin synergisms. We set a workflow allowing the identification of genes selectively modulated by a drug and possible novel drug interactions. To show its effectiveness, we selected trabectedin as a case-study drug. We retrieved eight transcriptional cancer datasets including controls and samples treated with trabectedi

SUBMITTER: Mannarino L 

PROVIDER: S-EPMC10888651 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature